Types of Cancer We Treat

Ovarian Cancer

Our gynecologic oncologists diagnose ovarian cancer and treat it using the latest surgical procedures, including minimally invasive, robotic-assisted, and fertility-sparing approaches and clinical trials.

Our gynecologic oncologists, genetic counselors, and fertility specialists offer services for women at an increased genetic risk of developing ovarian cancer. Our experts help you carefully consider whether screening or risk-reduction surgery is right for you.

We understand how important quick decisions are in treating ovarian cancer, so we generally see you within 48 hours of your appointment request. We complement cancer care with support services, including integrative health therapies, psychological support, genetic testing, and survivorship plans.

Meet Our Doctors
Dr. Douglas Levine
Our Approach to Ovarian Cancer Treatment Our Approach to Ovarian Cancer Treatment
Diagnosis
Ovarian Cancer Diagnosis
Surgery
Ovarian Cancer Surgery
Fertility-Sparing Procedures
Ovarian Cancer Fertility-Sparing Procedures
Chemotherapy & Targeted Drugs
Ovarian Cancer Chemotherapy and Targeted Drugs

Related News

Immunotherapy Unexpectedly Effective for Rare Ovarian Cancer
Read Story
A Better Understanding Emerges of Ovarian Cancer
Read Story
Study Suggests Most Ovarian Cancers Start in Fallopian Tubes
Read Story

Clinical Trials and Research Studies

Phase 3

A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer

Learn More

Phase 2/3

A RANDOMIZED PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER

Learn More

Phase 1

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Learn More

Phase 1/2

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Learn More
View All Related Clinical Trials (6)